Skip to content

Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression

Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01423773
Enrollment
20
Registered
2011-08-26
Start date
2011-08-31
Completion date
2011-12-31
Last updated
2013-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Comfort

Brief summary

The purpose of this study was to compare the fit and comfort of two types of contact lenses.

Detailed description

The relationship between ocular comfort and the Optical Coherence Tomography (OCT) measurements of post lens clearance and ocular tissue compression was studied.

Interventions

DEVICELotrafilcon A test contact lens

Silicone hydrogel single vision, soft contact lens with alternate parameters

DEVICELotrafilcon A control contact lens

Silicone hydrogel single vision, soft contact lens

DEVICEUltra-High Resolution Optical Coherence Tomographer (OCT)

Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear

Sponsors

Bascom Palmer Eye Institute
CollaboratorOTHER
CIBA VISION
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be of legal age of consent and sign Informed Consent document. * Normal binocularity. * Be able to wear soft contact lenses. * Willing to comply with the wear and study visit schedule. * Spherical contact lens prescription within 0.50 diopter of the available lens powers. * Spectacle cylinder less than or equal to 1.50 diopter. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Eye injury or surgery within twelve weeks of enrollment. * Pre-existing ocular irritation that would preclude contact lens fitting. * Currently enrolled in any clinical trial. * Evidence of systemic or ocular abnormality, infection, or disease likely to affect successful wear of contact lenses or use of accessory solutions as determined by the investigator. * Other protocol-defined

Design outcomes

Primary

MeasureTime frameDescription
Final ComfortDay 2, Hour 10Comfort was assessed by the participant on a Visual Analog Scale of 0 to 100, where 0=Extremely Uncomfortable (My eyes are in pain. I cannot tolerate my lenses) and 100=Extremely Comfortable (My eyes feel GREAT, better than normal. I cannot feel my lenses).

Countries

United States

Participant flow

Recruitment details

Partipants were recruited from one US study center.

Pre-assignment details

This reporting group includes all enrolled participants.

Participants by arm

ArmCount
Overall
Each product worn bilaterally for two consecutive days in either Period One or Period Two. A wash-out of 24 hours minimum to 3 weeks maximum separated the two periods.
20
Total20

Baseline characteristics

CharacteristicOverall
Age Continuous36.0 years
STANDARD_DEVIATION 10
Region of Enrollment
United States
20 participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 200 / 20
serious
Total, serious adverse events
0 / 200 / 20

Outcome results

Primary

Final Comfort

Comfort was assessed by the participant on a Visual Analog Scale of 0 to 100, where 0=Extremely Uncomfortable (My eyes are in pain. I cannot tolerate my lenses) and 100=Extremely Comfortable (My eyes feel GREAT, better than normal. I cannot feel my lenses).

Time frame: Day 2, Hour 10

Population: All enrolled participants

ArmMeasureValue (MEAN)Dispersion
Lotrafilcon A TestFinal Comfort87.6 Units on a scaleStandard Deviation 10.5
Lotrafilcon A ControlFinal Comfort87.9 Units on a scaleStandard Deviation 11.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026